Format

Send to

Choose Destination
Trends Mol Med. 2015 Jun;21(6):394-402. doi: 10.1016/j.molmed.2015.03.003. Epub 2015 Apr 3.

Tau immunotherapy for Alzheimer's disease.

Author information

1
Neurodegeneration, H. Lundbeck A/S, DK-2500 Valby, Denmark. Electronic address: jatp@lundbeck.com.
2
Departments of Neuroscience and Physiology, and Psychiatry, New York University School of Medicine, New York, NY 10016, USA. Electronic address: einar.sigurdsson@nyumc.org.

Abstract

Targeting pathological tau protein in Alzheimer's disease (AD) and related tauopathies has shown great potential in animal models. Given that tau lesions correlate better with the degree of dementia than do amyloid-β (Aβ) plaques, their clearance may be clinically more efficacious than removing Aβ when cognitive deficits become evident in AD. Several complementary mechanisms of antibody-mediated removal of tau aggregates are likely to act in concert and the importance of each one may depend on antibody properties, the disease, and its stage. Clinical trials of tau immunotherapy are already underway and several more are likely to be initiated in the near future.

KEYWORDS:

Alzheimer's disease; immunotherapy; tau protein; tauopathies

PMID:
25846560
DOI:
10.1016/j.molmed.2015.03.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center